eClinical Technology and Industy News

Boosting Accuracy and Patient Comfort in Prostate Cancer Treatment Planning

Excerpt from the Article:

One of the most common cancers among men in the United States, prostate cancer is second in prevalence only to skin cancer. Approximately 12.5 percent of men will be diagnosed with prostate cancer at some point during their lifetimes. Put another way, out of every 100 American men, approximately 13 will get prostate cancer during their lifetime, and about two-to-three men will die from it, according to the Centers for Disease Control and Prevention (CDC).

Even so, survival rates for prostate cancer are generally good, with a five-year relative survival of 97.5 percent. Survival is high because many prostate cancers grow slowly or not at all. The goal of screening is to detect cancers that may grow if not treated.

Once detected, there are multiple ways to treat prostate cancer. Every patient is different. What works for one patient may not be the best solution for another patient. There is no single roadmap.

Click the button below to read the entire Article:

Continue Reading The Article

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives